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In a previous paper (Burtin et al., 1982), we
demonstrated that the i.p. daily injection of
serotonin to mice carrying methylcholanthrene-
induced fibrosarcomas inhibited tumour growth
and lengthened survival of mice. We suggested that
increased vascular permeability played an essential
role, which probably assisted the intratumoral
penetration of host immune anti tumour elements.
The effects of serotonin on the blood vessel wall
are complex. They include venous constriction,
contraction of most arterial and venous smooth
muscle, arterior dilation and inhibition of
peripheral adrenergic neurotransmission. Thus, in a
given vascular bed, the net effect is determined by
the balance between the vasoconstrictor and the
vasodilator action (Van Nueten, 1982). Because
of the pathologic character of tumour
vascularization, (Karlsson et al., 1980, Denekamp
& Hobson, 1982, Shubik, 1982) the effect of
vasoactive drugs on tumours is often different from
that on normal tissues. Vasoconstrictors, such as
isoprenaline (Mattsson et al., 1982) do not
influence tumour blood flow, suggesting that the
tumour vascular bed is normally in a state close to
maximal dilation (Karlsson et al., 1983; Mattsson,
1980; Mattsson et al., 1982). It was even
demonstrated that vasodilators, such as
acetylcholine (Young et al., 1983) or papaverine
(Karlsson et al., 1983) decrease tumour blood flow.
The activity of serotonin on tumour blood flow
and tumour vascular permeability is not known. In
order to investigate the mechanism of action of
serotonin on tumour growth, the penetration of
spleen cells in tumour, spleen and striated muscle
was determined with or without serotonin
treatment. The possibility of influencing the
intratumoral distribution of immune cells would be
of great clinical interest. Labelled spleen cells were
injected into tumour-bearing mice after
administration of serotonin, according to the
method described by Salomon et al. (1981).
The MC B6-1 fibrosarcoma was originally
induced by s.c. injection of 2 mg
methylcholanthrene in a female C57 BL/6 mouse,
serially transplanted in syngeneic mice, and used
between the 20th and the 25th passage. C57BL/6
mice, 6-20 weeks old, received 104 tumour cells s.c.,
and were used at different times after inoculation.
Serotonin (5-hydroxytryptamine and creatinin
sulfate, Prolabo) was injected i.p., 1 mg per animal
in 0.2ml medium. Normal spleen cells were labelled
with radioactive sodium chromate (51Cr, specific
activity: 1 mCiml-1); these cells, 5-8 x 106,
containing 1-2x 105cpm, in 0.1ml, were injected
i.v. to each animal.
Groups of tumour-bearing animals (4-5 per
group) received either serotonin or minimal
essential medium i.p. One hour later, all groups
received labelled spleen cells. One hour later, in a
control group and in a serotonin-treated group,
tumour, spleen and striated muscle (quadriceps)
were removed, individually weighted and counted in
a scintillation counter. Four hours after inoculation
of spleen cells, another control group and another
serotonin-treated group were similarly treated. For
each animal, cpmmg-1 of organ were calculated.
Results are expressed as mean + s.e. c.p.m. mg-'
organ weight and analyzed by the Student's t test.
In spleen and muscle of small and medium-sized
tumour bearing mice, h or 4h after spleen cell
injection, serotonin treatment induced either no
modification in the radioactivity or a decrease in
the spleen and an increase in the muscle (Table I).
In contrast, in the tumour, penetration was
increased in both experiments. In the relatively
small tumours (mean wt, 251 mg) the increase was
detected at I h, and was highly signifilcant at 4h. In
the medium-sized tumours (mean wt, 534mg) the
increase was detected only at 4h.
In order to determine whether penetration was
more greatly modified by serotonin in small
tumours than in large tumours, we compared the
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Table I Uptake of 51Cr labelled spleen cells in spleen,
muscle & tumour of tumour-bearing mice
Time after
spleen cell
injection
Expt. 1 1 h Spleen
Muscle
Tumour
4h Spleen
Muscle
Tumour
Expt. 2 1 h Spleen
Muscle
Tumour
4h Spleen
Muscle
Tumour
cpm mg - (mean+se)
Control Serotonin
112+ 11
0.80+0.09
1.35+0.07
144+ 11
0.77+0.02
1.20+0.07
315 +22
0.48 +0.05
1.49+0.15
391 +61
0.86+0.06
1.35+0.12
97+9
1.53+0.16
2.61 +0.66
139+ 11
1.03+0.07
2.09+0.12
171 +40
0.98 +0.17
1.25+0.14
393 +56
1.16+0.10
2.02+0.28
p
NS
<0.01
<0.05
NS
<0.01
<0.001
<0.02
<0.05
NS
NS
NS
<0.05
Experiment 1: mean tumour weight (mg) 251 +23
Experiment 2: mean tumour weight (mg) 534+61
Table II Uptake of 5'Cr labelled spleen cells, 4h after
injection, in spleen, muscle & tumour, as a function of
transplanted tumour size
cpm mg ' (mean+se)
Control Serotonin P
Small tumours
Spleen 290+20 263 + 11 NS
Muscle 0.93+0.13 0.81 +0.04 NS
Tumour 2.06+0.21 4.00+0.80 <0.05
Large tumours
Spleen 48+ 18 31+6 NS
Muscle 1.05 +0.42 0.97+0.06 NS
Tumour 0.97+0.17 1.44+0.26 NS
Small tumours: mean tumour weight (mg) 184+41
Large tumours: mean tumour weight (mg) 2370+ 131.
Table III Relationship between
tumour size and uptake of "Cr
labelled spleen cells, 4h after
injection
Mean tumour % control in
weight (mg) serotonin-treated
184 194
251 174
534 150
2370 148
penetration in small tumours (mean wt, 184mg)
and in very large tumours (mean weight 2.370g),
4h after spleen cell injection.
Table II shows that c.p.m. mg of tumour are
much more elevated in small tumours, treated or
not by serotonin, and that serotonin induced a
nearly 2-fold increase in cell penetration in small
tumours, and only a non-significant increase in
large tumours.
Thus the results as a whole show that the percent
increase in cell penetration induced by serotonin
treatment, measured 4h after spleen cell injection,
was greater in small tumours than in large ones
(Table III).
Because of the complexity of the activity of
serotonin on vessel walls and the disorganization of
tumour vasculature, the effect of serotonin on
tumours could not be anticipated. Indeed, we
observed an increase in penetration of spleen cells
in tumour, a slight decrease or no effect in muscle;
studies showing a state of maximal dilation
(Mattsson et al., 1982) and the absence of
autoregulation (Suzuki et al., 1981) of tumour
vessel walls suggest that passive vascular beds are
not responsive, and may be secondarily influenced
by the responding somatic vessels connecting with
tumour vessels (Suzuki et al., 1981). The method
used here does not allow us to determine whether
the mechanism of action of serotonin is direct or
indirect, but does illustrate the final result of
increased penetration of lymphoid cells inside the
tumour.
The well known phenomenon of preferential
homing of lymphocytes in the spleen (Ford, 1975)
was observed since radioactivity per mg of organ
was 100-300 times more elevated than in the
tumour and the muscle; however, serotonin did not
increase this penetration. Penetration was lower in
the muscle than in the tumour and the elevation
induced by serotonin in the former tissue was
inconsistent. By contrast, the serotonin effect was
important in small tumours, where it induced a
nearly 2-fold increase in spleen cell penetration,
which decreased progressively with tumour growth.
It is known that, with increasing size, the
proportion of effective vascularization decreases
(Denekamp & Hobson, 1982) and the plasma
volume is relatively reduced (Karlsson et al.,
1980). However, the effect of serotonin remains
significant on tumours of 534mg, grafted 20 days
before testing.
In previously described experiments (Burtin et al.,
1982) we observed that serotonin treatment reduced
tumour growth. This antitumour effect of serotonin
was observed even when treatment was begun in
mice bearing medium size tumours. Histological
examination showed the presence of bands and fociENHANCEMENT BY SEROTONIN OF INTRATUMOR PENETRATION 547
of necrotic and haemorrhagic tissue in the tumours
of mice treated with serotonin.
Serotonin is the most important agent for
increasing vascular permeability in mice (Schartz et
al., 1977). It plays an important role in the
migration of lymphocytes to the site of delayed-
type hypersensitivity (Gershon et al., 1975;
Askenase et al., 1982). It has been suggested that
vasoactive amines are important in the recruitment
of inflammatory cells into tumours (Lynch &
Salmon, 1977). It could increase, within the
tumour, infiltrating elements with an antitumour
activity (Klein et al., 1980).
However, the vascular effect of serotonin is
perhaps not sufficient to explain its antitumoral
activity. In vitro experiments showed that mast cells
were cytotoxic to mouse fibrosarcoma cells.
Reserpine blocked tumour killing, suggesting
serotonin as the principal agent of tumour cell
killing by mast cells. (Farram & Nelson, 1980).
The increase in mast cell number demonstrated in
tissues of tumour bearing mice (Galoppin et al.,
1984) could play an important role in antitumour
defense, acting by more than one mechanism.
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